The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“The most common variant, G2019S, occurs within the LRRK2 kinase activation loop and results in increased kinase activity (West et al., 2005; Greggio et al., 2006).”
LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress
Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R. E., Langston, W., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.01.013 · Cited by 745
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605 · cited 3×
“In addition to exploring the role of LRRK2 kinase activity in lung, we also evaluated the disease-modifying potential of MLi-2 in the MitoPark mouse model of PD (Ekstrand et al., 2007).”
BackgroundMethodInfluentialKachergus, J., Mata, I. F., Hulihan, M., Taylor, J. P., Lincoln, S., Aasly, J., Gibson, J. M., Ross, O. A., Lynch, T., Wiley, J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429256 · Cited by 541
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539
Localization of LRRK2 to membranous and vesicular structures in mammalian brain
Biskup, S., Moore, D. J., Celsi, F., Higashi, S., West, A. B., Andrabi, S. A., Kurkinen, K., Yu, S., Savitt, J. M., Waldvogel, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21019 · Cited by 511
Cited by
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 1,042
Self-citationLRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Steger, M., Diez, F., Dhekne, H. S., Lis, P., Nirujogi, R. S., Karayel, O., Tonelli, F., Martinez, T. N., Lorentzen, E., Pfeffer, S. R., et al. (2017) · eLife · doi:10.7554/elife.31012 · Cited by 482
Deyaert, E., Wauters, L., Guaitoli, G., Konijnenberg, A., Leemans, M., Terheyden, S., Petrovic, A., Gallardo, R., Nederveen-Schippers, L. M., Athanasopoulos, P. S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01103-4 · Cited by 457
Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., Chou, M.-Y., Howden, A. J. M., König, T., Hotzy, C., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180248 · Cited by 222
Ito, G., Katsemonova, K., Tonelli, F., Lis, P., Baptista, M. A. S., Shpiro, N., Duddy, G., Wilson, S., Ho, P. W.-L., Ho, S.-L., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160557 · Cited by 183
Fan, Y., Howden, A. J. M., Sarhan, A. R., Lis, P., Ito, G., Martinez, T. N., Brockmann, K., Gasser, T., Alessi, D. R., & Sammler, E. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170803 · Cited by 173
Perspective on the current state of the LRRK2 field
Taymans, J.-M., Fell, M., Greenamyre, T., Hirst, W. D., Mamais, A., Padmanabhan, S., Peter, I., Rideout, H., & Thaler, A. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00544-7 · Cited by 153
Self-citationLis, P., Burel, S., Steger, M., Mann, M., Brown, F., Diez, F., Tonelli, F., Holton, J. L., Ho, P. W., Ho, S.-L., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20170802 · Cited by 151
PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins
Berndsen, K., Lis, P., Yeshaw, W. M., Wawro, P. S., Nirujogi, R. S., Wightman, M., Macartney, T., Dorward, M., Knebel, A., Tonelli, F., et al. (2019) · eLife · doi:10.7554/elife.50416 · Cited by 139
Singh, F., Prescott, A. R., Rosewell, P., Ball, G., Reith, A. D., & Ganley, I. G. (2021) · eLife · doi:10.7554/elife.67604 · Cited by 131
Kalogeropulou, A. F., Purlyte, E., Tonelli, F., Lange, S. M., Wightman, M., Prescott, A. R., Padmanabhan, S., Sammler, E., & Alessi, D. R. (2022) · Biochemical Journal · doi:10.1042/bcj20220161 · Cited by 129
Khan, S. S., Sobu, Y., Dhekne, H. S., Tonelli, F., Berndsen, K., Alessi, D. R., & Pfeffer, S. R. (2021) · eLife · doi:10.7554/elife.67900 · Cited by 93
LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients
Atashrazm, F., Hammond, D., Perera, G., Bolliger, M. F., Matar, E., Halliday, G. M., Schüle, B., Lewis, S. J. G., Nichols, R. J., & Dzamko, N. (2019) · Movement Disorders · doi:10.1002/mds.27601 · Cited by 102
Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
Streubel-Gallasch, L., Giusti, V., Sandre, M., Tessari, I., Plotegher, N., Giusto, E., Masato, A., Iovino, L., Battisti, I., Arrigoni, G., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02327-8 · Cited by 100
Association of a common genetic variant with Parkinson’s disease is mediated by microglia
Langston, R. G., Beilina, A., Reed, X., Kaganovich, A., Singleton, A. B., Blauwendraat, C., Gibbs, J. R., & Cookson, M. R. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8869 · Cited by 93
Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2
Waschbüsch, D., Purlyte, E., Pal, P., McGrath, E., Alessi, D. R., & Khan, A. R. (2020) · Structure · doi:10.1016/j.str.2020.01.005 · Cited by 87
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Cornblath, E. J., Li, H. L., Changolkar, L., Zhang, B., Brown, H. J., Gathagan, R. J., Olufemi, M. F., Trojanowski, J. Q., Bassett, D. S., Lee, V. M. Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg6677 · Cited by 66
Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubules
Snead, D. M., Matyszewski, M., Dickey, A. M., Lin, Y. X., Leschziner, A. E., & Reck-Peterson, S. L. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00863-y · Cited by 54
Self-citationRAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A
Madero-Pérez, J., Fernández, B., Lara Ordóñez, A. J., Fdez, E., Lobbestael, E., Baekelandt, V., & Hilfiker, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00417 · Cited by 48
Kakade, P., Ojha, H., Raimi, O. G., Shaw, A., Waddell, A. D., Ault, J. R., Burel, S., Brockmann, K., Kumar, A., Ahangar, M. S., et al. (2022) · Open Biology · doi:10.1098/rsob.210264 · Cited by 42
“Reagents [γ-32P] ATP was from PerkinElmer, MLi-2 was obtained from Merck [14].”
MethodSmall-Molecule Inhibitors of LRRK2
Hatcher, J. M., Choi, H. G., Alessi, D. R., & Gray, N. S. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_13 · Cited by 39
Parkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B
Pal, P., Taylor, M., Lam, P. Y., Tonelli, F., Hecht, C. A., Lis, P., Nirujogi, R. S., Phung, T. K., Yeshaw, W. M., Jaimon, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj1205 · Cited by 36
Xenias, H. S., Chen, C., Kang, S., Cherian, S., Situ, X., Shanmugasundaram, B., Liu, G., Scesa, G., Chan, C. S., & Parisiadou, L. (2022) · Communications Biology · doi:10.1038/s42003-022-04136-8 · Cited by 32
Brzozowski, C. F., Hijaz, B. A., Singh, V., Gcwensa, N. Z., Kelly, K., Boyden, E. S., West, A. B., Sarkar, D., & Volpicelli-Daley, L. A. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01283-7 · Cited by 32
RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors
Dou, D., Aiken, J., & Holzbaur, E. L. F. (2024) · Journal of Cell Biology · doi:10.1083/jcb.202307092 · Cited by 29
Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2
Evans, L. D., Strano, A., Tuck, E., Campbell, A., Smith, J., Hung, C., Behr, T. S., Ghetti, B., Ryskeldi-Falcon, B., Karakoc, E., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00514-0 · Cited by 16
Fenner, B. M., Fenner, M. E., Prowse, N., & Hayley, S. P. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30588 · Cited by 14
“Moreover, MLi‐2 was exceptionally potent and selective for LRRK2 (compared to a broad range of kinases and ion channel receptors) in kinase and radioligand competition binding assays (Fell et al., 2015).”
BackgroundStructure and regulation of full-length human leucine-rich repeat kinase 1
Metcalfe, R. D., Martinez Fiesco, J. A., Bonet-Ponce, L., Kluss, J. H., Cookson, M. R., & Zhang, P. (2023) · Nature Communications · doi:10.1038/s41467-023-40532-2 · Cited by 8
Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2
Chen, S., Basiashvili, T., Hutchings, J., Sanz Murillo, M., Villagran Suarez, A., Xiong, E., Alegrio Louro, J., Leschziner, A. E., & Villa, E. (2025) · eLife · doi:10.7554/elife.100799.3 · Cited by 3
Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2
Chen, S., Basiashvili, T., Hutchings, J., Sanz Murillo, M., Villagran Suarez, A., Xiong, E., Alegrio Louro, J., Leschziner, A. E., & Villa, E. (2025) · eLife · doi:10.7554/elife.100799 · Cited by 1
Metadata
- Authors
- Fell, M. J., Mirescu, C., Basu, K., Cheewatrakoolpong, B., DeMong, D. E., Ellis, J. M., Hyde, L. A., Lin, Y., Markgraf, C. G., Mei, H., Miller, M., Poulet, F. M., Scott, J. D., Smith, M. D., Yin, Z., Zhou, X., Parker, E. M., Kennedy, M. E., & Morrow, J. A.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 355
- Issue
- 3
- Pages
- 397-409
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2272666074
- Cited by
- 305
- References
- 32
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.